Gilead Sciences Inc Stock Moved Up by 6.45% on Feb 11: What Investors Need To Know

Gilead Sciences (GILD) experienced a notable upward movement in its stock price, largely driven by positive fourth-quarter financial results for 2025 and subsequent analyst upgrades. The company reported earnings per share that surpassed consensus estimates, alongside revenue that also exceeded expectations. This strong financial performance was primarily attributed to robust sales in its core HIV and liver-disease franchises, particularly the successful launch of Yeztugo, a twice-yearly HIV prevention therapy.

Despite some investor focus on an initial lower fiscal year 2026 guidance, the overall sentiment turned positive as multiple financial analysts reiterated or upgraded their ratings and significantly raised price targets for GILD shares. Firms such as JPMorgan Chase & Co., Needham, Scotiabank, Cantor Fitzgerald, Morgan Stanley, BofA Securities, and Wells Fargo increased their price targets, citing confidence in Gilead's HIV segment momentum and potential for margin expansion, as well as the strong performance in oncology.

Additionally, recent regulatory developments contributed to the positive market reaction. On February 6, 2026, the FDA approved an update to the prescribing information for Yescarta, a Gilead CAR T-cell therapy, removing previous Limitations of Use for a rare and aggressive form of lymphoma. This update reflects robust safety data and expands the potential application of the therapy, indicating progress in Gilead's oncology pipeline. The company's strategic pivot towards oncology, alongside continued innovation in HIV treatment, has been recognized by analysts as reshaping its investment case, contributing to a strong market perception. The company's management also highlighted multiple catalysts expected in 2026, including potential new launches in cancer therapies and an additional HIV treatment option.

Technically, Gilead Sciences Inc (GILD) shows a MACD (12,26,9) value of [5.64], indicating a buy signal. The RSI at 68.11 suggests neutral condition and the Williams %R at -24.45 suggests oversold condition. Please monitor closely.

Gilead Sciences Inc (GILD) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is 29.44B, ranking 16 in the industry. The net profit is 8.51B, ranking 7 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as BUY, with an average price target of 139.53, a high of 159.00, and a low of 103.00.

Company Specific Risks:

• Gilead's fiscal year 2026 revenue guidance, projected between $29.6 billion and $30.0 billion, falls below analyst consensus estimates of approximately $30.1 billion, contributing to near-term stock pressure.
• The company anticipates a 10% decline in cell therapy revenue in fiscal year 2026 due to continued competitive pressures, with Tecartus sales specifically decreasing by 9% in Q4 2025 compared to the prior year.
• Projected sales for the Yeztugo product are approximately $800 million, which is below the consensus estimate of $922 million, and management has expressed conservatism regarding patient adherence.
• The company faces oncology execution risk, as evidenced by the ASCENT‑07 miss for Trodelvy and the discontinuation of domvanalimab/zimberelimab gastric studies.